Recently, a study with a large cohort of matched primary and recurrent IDH-wildtype GBM has shown that MGMT promoter methylation status differs between primary and recurrent tumors, and MGMT methylation status remains predictive for TMZ response in tumor recurrence37. Here, IDH1 is linked to glioblastoma.